Chemotherapeutic Resistance Genes of Breast Cancer Patients - An Overview

Anagha Kollampambil Ajith, Sasikala Subramani, Agaath Hedina Manickam, Sivasamy Ramasamy

Molecular Genetics and Cancer Biology Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore-641 046.

Abstract

Purpose: Cancer is the leading challenge to human health since the dawn of early Egyptian manuscripts, where they found tumour from fossils in the modernized 20th century. Increasing rate of incidence and death from cancer in the past few years is thought provoking. Among all type of cancers, breast cancer is very common among women and diverse in character. Drug resistance is the challenging aspect for traditional chemotherapy.

Methods: Data was collected from online platform without any time restriction. After screening and evaluation, 66 articles were considered for this study. This review is a summarized collection of information from published studies on human genes associated with drug resistance in breast cancer treatment.

Results: Analysis of these findings highlights the importance of MAP kinase and ABC gene families in creating resistance barriers. Genes involved in cell cycle alteration, apoptosis, and hippo pathway were also linked with drug resistance particularly in breast cancer.

Conclusion: The exact mechanism of chemotherapy resistance is still unresolved and unexplained the drug resistance seen in breast cancer patients were multifactorial. Drug induced up regulation or down regulation of genes contributes unusual protein expression and ultimately leads to resistance. The ultimate focus of this review is to identify the genes having pivotal role in chemotherapy resistance in breast cancer.

Introduction

Abnormal growth of cells due to uncontrolled cell proliferation in body is called as cancer. Breast cancer is one of the world’s commonest cancers with a collection of neoplastic diseases that are molecularly and clinically complicated and comprise different sub types with unique characters. Breast cancer is rarely seen in males. Being a highly prevalent cancer type, it is observed in both developing and developed countries with different causes and factors of progression. Adopting new life styles, industrialization, globalization, increased life expectancy, pollution etc are the leading cause of cancer. 2012 Global Cancer statistics reveals that among the eight million diagnosed cases of cancer all over the world, one million constitute of breast cancer. According to 2015 cancer statistics almost 231 000 US women were diagnosed and about 40 000 patients were died with breast cancer. As per 2018 statistics, every year around 1.2 million new cases of breast cancer were diagnosed. The GLOBACON report of 2018 concluded breast cancer as the most frequently identified cancer type and leading cause of cancer related death in majority of the countries. Major part of breast related cancer are linked with the expression of estrogen receptor and their treatment is related with the disease prognosis.

Rate of breast cancer mortality can be reduced up to a limit by early diagnosis; timely treatment and management commonly adopted treatment strategies for breast cancer are chemotherapy, radiation therapy and hormone therapy. Among them chemotherapy is widely accepted as traditional treatment method, in spite of its obstacle due to chemotherapy resistance. Important mechanisms lead to drug resistance includes alteration in expression of ABC transporters gene family, damage of topoisomerase enzyme, mutation in DNA repair genes, induced apoptosis by genetic imbalance, alteration in signalling pathways of NF alpha etc. All these worsen the condition of breast cancer making chemotherapy a failure in most cases. The cells which already acquired drug resistance show cross resistance to anti proliferative nature of anti-oestrogen drugs which have crucial role in breast cancer treatment. In this review, we are discussing on various genes involved in chemotherapy resistance pathways of breast cancer.

Genes involved in MAP kinase pathway

Mitogen activated protein kinase (MAPK) is a group of protein which communicates and transfers signal from
the cell surface to the nuclear environment in response to external stimuli. Alteration in MAPK pathway cause poor tamoxifen response in ductal carcinoma and estrogen expression in lobular breast cancer. Copy number alteration and mutation acquired by drug resistant cells affect the metallotropic glutamate receptor and MAPK pathway. MAP deregulation induces tamoxifen resistance. Likewise the hyperactivity of MAPK is closely linked with GRM1 gene mutation. The GRM1 gene is considered as an oncogene in epithelial cells. Un controlled expression of the KLF4 gene, plays an important role in the transition of G1 to S phase through P53. Phosphorylation of MAPK pathway and estrogen receptor kinase and P38 activation were induced by KLF4 knock down causing tamoxifen resistance. Hyperactivity of MAPK signalling by the c-ras, b-raf, MEK ½ mutation is commonly seen in many human cancer cells including breast cancer. MAPK/ERK pathway regulates cell cycle and cell proliferation having a crucial role in cancer treatment especially in triple negative breast cancer cases. Heterodimerization of RAF kinase cause the activation of ERK pathway and drug resistance. Demodulation of Jak, stat 3 and Akt signalling along with MAP kinase pathway cause paclitaxel resistance by STAT3 in breast cancer, and also the basal activity of JAK1/STAT1 and JAK1/STAT3 signalling is higher in chemo resistant cells. The Genes of STAT3 Inhibition involved in apoptosis activation is down regulated in chemotherapy resistant cells.

**Genes associated with drug efflux**

Efflux proteins are involved in the transportation of drugs and toxic substance from inside the cell to the outside ATP dependent drug efflux pumps may sometimes reduce drug uptake. ABCD1, C1, and G2 transporters are extensively studied ABC transporters gene family involved with drug resistance.

**The ATP-binding cassette (ABC) transporters**

ABCG2 gene is commonly known as BCRP which is a part of ATP binding cassette transporters that play a major role in cellular transportation by the expense of ATP across concentration gradient inducing drug resistance mechanism. Various anti cancers agents’ effluxed by altered expression of p-glycoproteins are considered most studied and explained mechanism of drug resistance. P-glycoprotein is an example of adenosine triphosphate binding cassette protein, which expressed by the mutation of genes in ABC family and drug doxorubicin, acquires resistance through the mutation of this gene family. This in turn because drug effects leading to insufficient accumulation of doxorubicin in nucleus, showing only about 0.4% doxorubicin enter cell after internalization.

Recent research points out multiple drug resistance induced by oxidized low density lipoproteins and very low-density lipoproteins. Down regulation of p-glycoproteins by these lipoproteins induce alteration in ABCB1 gene expression, paving the way for multiple drug resistance through drug efflux. Many study reveals that the cells treated with epirubicin and anthracycline, show ABCG2 activation and expression in breast cancer cell lines by self-renewing capacity. ABCG2 gene has an important role in gefitinib resistance. Which is used for EGFR over expressed breast cancer like erlotinib. These drugs interrupt EGFR signaling in the target cells. Drug induced over expression of proteins by ABCG2 genes acquire resistance to the drug gefitinib in EGFR expressed breast cancer cells. At low concentration gefitinib act as a substrate for ABCG2 protein, inducing gefitinib resistance through Akt nuclear EGFR (nEGFR) pathway. ABCI gene family induce drug efflux causing resistance to methotrexate, and up regulation of GPR120 gene cause alteration in GRP120 protein mediated signaling, inducing resistance to epirubicin in chemotherapy, and Akt NFkB signaling is responsible for GRP120 mediated resistance to epirubicin. Intracellular epirubicin accumulation is directly associated with ABC transporters expression ABCG1 and ABCG2 gene up regulation by NF-kb p65 cause blockage of GPR120 signaling. FASN and ABCG2 expression is decreased by GPR120-si-RNA and GP6120 expression is related with the levels of ACC1, ABCC2, FASN and FFAs. All these are directly or indirectly related to ABC gene up regulation and multiple drug resistance.

**Multiple drug resistant genes**

ABC gene family members MDR1 have a significant role in drug resistance. MDR1 over expressions by p53 alteration cause chemo resistance in doxorubicin and Tuxol. Which significantly contributes changes in P-glycoprotein levels there by inducing resistance. Acquired and intrinsic cross resistance to vinca alkaloid derived drugs and anthracycline are related to p-glycoproteins induced MDR1 expression. Deletion of the mir 125b gene in chromosome 19q and microRNA 451 regulate MRD1expression in anthracycline induced resistance.

**Cell cycle alternating genes**

Chemotherapy cause changes in genes involved in cell proliferation by holding the cell division, where FOX protein family have a significant role in regulating cell cycle. Studies report over expression of the androgen receptor as a reason for chemotherapy resistance, contributes uncontrolled cell proliferation in triple negative breast cancer patients. FOXA1 is an inhibitor of AR signaling by detecting it is binding to the cells, whose activity completely overlaps estrogen receptor binding site in an AR positive cells lines and cause tamoxifen resistance. GRLH2 binding site is closely associated with FOXA1 binding site. Tamoxifen resistance result in LYPD3 protein level elevation, which is considered as a target for GRHL2. One of the reasons for HER2 mediated drug resistance is by the amplification or
deletion of Topoisomerase II alpha gene $\text{TOP2A}$ located in 17q21 near to ERBB2 oncogene.$^{39}$ Topoisomerase II alpha is the molecule target for topo II inhibitors, potent anti-cancerous drug.$^{30}$

**Genes mediated drug resistance through preventing apoptosis**

Apoptosis pathways have a significant role in cancer treatment, and any alteration in this pathway is a major obstacle for effective treatment.$^{31}$ Two routes are involved in the activation of apoptosis cascade. The intrinsic pathway also known as mitochondrial pathway that releases cytochrome C by activation of tumor necrosis factor in response to ligand binding.$^{32}$ Autophagy, mitotic catastrophe, necrosis, and senescence are non-apoptosis mechanism involved in cell death.

CASP3 gene is located in the 4q34 with size 2635 bp, this mediates apoptosis in response to chemotherapy, but losing caspase 3 activity cause cell survival and induce drug resistance through apoptotic pathway in breast cancer.$^{33}$

$\text{K1F14}$ is a tumor inhibitor gene that prevents cell migration and induce cell apoptosis and its knockdown is found increases breast cancer subjects.$^{34}$ $\text{K1F14}$ plays an important role in drug resistance by enhancing cell proliferation through $\text{Akt1}$ pathway which with decreased activation lowers the level of Akt and affects the $\text{P13K/ Akt}$ signaling that controls the apoptosis pathway. It also decreases the levels of tumour suppressor gene $\text{p63}$, promoting $\text{Akt}$ phosphorylation. Docetaxel is one of the frequently used drugs for breast cancer and decreased $\text{K1F14}$ expression increase docetaxel resistance.$^{35}$ $\text{FOXM1}$ is a cell proliferation gene which encodes a protein regulating cell cycle gene and also an apoptosis inhibitor. $\text{XIAP}$ produces protein for preventing apoptosis and survivin is produced by $\text{BIRC5}$, whose expression covers upregulation in drug resistance. $\text{XIAP}$ and $\text{BIRC5}$ induce taxane and anthracycline resistance.$^{37}$ Survivin, induce multiple drug resistance to drugs in tumors associated with endothelial cells causing resistance to drugs like paclitaxel and temozolomide by preventing apoptosis of caspase 7 and 4.$^{38}$

O6 methyl guanine methyl transferase is a DNA repair enzyme, whose increased activity causes resistance to drug such as temozolomide, streptozotocin, procarbazine and dacarbazine. This induces DNA lesions.$^{39}$ The genes $\text{XRCC2}$ and $\text{BRCA2}$ involved in homologous recombination and DNA damage repair. This confers cisplatin induced drug resistance by maintaining DNA damage.$^{40}$ $\text{XRCC2}$ stimulates $\text{RAD51}$ levels and Elevated $\text{RAD51}$ level is linked with high recombination rate and increases resistance to DNA altering drugs.$^{40}$ $\text{XRCC2}$ expression is directly linked with drug resistance by different mechanisms.$^{41}$

$\text{ASK1}$ gene is a $\text{MAP3 K}$ member which plays a vital role in breast cancer cell apoptosis under stress conditions. Raf 1 mediated inhibition of $\text{ASK1}$ cause drug resistance in endothelial cells through basic fibroblasts growth factor. Pro apoptotic activity of this gene is inhibited by BFGF, which leads to the end of apoptosis.$^{42}$ $\text{ASK1}$ gene’s level is related with $\text{CLDN6}$ expression and over expression of $\text{CLDN6}$ is linked with breast cancer chemo resistance through GSTP1 its activity is regulated by $\text{p53}$. In the treatment of hormone sensitive breast cancer, tamoxifen resistance is a clinical obstacle. The major genes involved in tamoxifen resistance by X box binding proteins. Which is directly related with estrogen receptor alpha function. First three amino acids of the protein coding gene involved in the activation of estragon receptor in estrogen deficiency.$^{43}$ Tamoxifen also targets the mitochondrial genes like $\text{SIRT3}$ and $\text{AMPK}$. The protein encoded by $\text{SIRT3}$regulates ATP generation, aging and carcinogenesis. It has a significant role in inhibiting apoptosis and recent studies show the evidence of this gene in drug resistance.$^{44}$ This drug up regulates the $\text{SIRT3}$ gene function and $\text{AMPK}$ gene phosphorylation. Where $\text{AMPK}$ has a crucial role in drug resistance by producing self-renewal cancer stem cells.$^{45}$ $\text{AMPK}$ also act as a downstream regulator of tumour suppressor genes like $\text{P53}$ and $\text{LKB1}$. Tamoxifen regulates estrogen modulation through non genomic and genomic signalling$^{46}$ (Figure 1).

Chemotherapy increases the expression of $\text{BHLH}$ genes. Anti-cancerous drugs which acts on Microtubule in a disruptive manner induces drug resistance by up regulation of $\text{TWIST}$ gene.$^{47}$ Likewise knockdown of $\text{SPZ1}$ have a crucial role in chemotherapy resistance through $\text{TWIST}$ gene alternation$^{48}$ (Figure 2).

The anti-cancer drugs used for DNA repair can induce drug resistance through the same mechanism, whereas DNA mismatch repair gene like $\text{MSH2}$ and $\text{MLH1}$causes resistance to topoisomerase II inhibitor doxorubicin and mitoxantrone.$^{49}$

**Drug inactivation**

Drug inactivation phenomenon refer to the decreasing amount of free drug available in the cell to be detected and bind to a particular intracellular target. Chemotherapeutic Platinum drugs covalently links to glutathione related enzymes and promote drug efflux by acting as a substrate complex for the ABC transporters protein.$^{50}$ The glutathione linking is catalyzed by the glutathione-transferase enzyme family. High level of GST- $\pi$ is a reason for cisplatin induced drug resistance.$^{51}$ Where $\text{P}$ glycoproteins related with GST II also causes multiple drug resistance. Paclitaxel cause over expression of $\text{GSTII}$ and the GST family protein is considered as a bad prognostic indicator for drug resistance.$^{52}$

**Cancer stem cells**

The knowledge of cancer stem cell opens a new insight in the study of oncogenesis and cancer treatment.$^{53}$ The characteristic features of the stem cells differentiate it
from normal cells and in addition to its self-renewal property it can stay in a state of dormancy and infrequent division. Requiring special environmental conditions for division. ABC transporters gene family have a significant role in chemotherapeutic agents induced formation of cancer stem cells in breast cancer. ABCG2 and ABCB1 are the important genes involved in the formation of cancer stem cells and MYC and MYCL are another gene involved in drug resistance by different mechanism and most important method is promoting colony formation capacity. Stem cells which is formed as a result of chemotherapy cause colonization of cancer at different places. MYC carries out cell proliferation and apoptosis; in TP53 mutation MYC and MYCL are co amplified. This directly results in the breast cancer stem cells enrichment by enhancing mitochondrial respiration. It also upregulates ROS production in breast cancer (Figure 3).

**Genes associated with hippo pathway**
Hippo pathway is identified first in Drosophila Melanogaster, and later identified in mammals. Core components are Kinase MST1/2 (mammalian Ste-20 like kinase), LAST 1/2 (large tumour suppressor), YAP (yes associated protein), TAZ (transcriptional co activator with PD2), RASSF1. Hippo pathway is activated by MST1/2. Transcription of YAP and TAZ are inhibited by the phosphorylation and down regulation of LAST1/2. Hippo pathway activation is closely related with breast cancer stem cell formation. Breast cancer stem cell’s improper TAZ and YAP activity cause multiple drug resistance. An anti-Microtubule drug taxol cause LAST2 knockdown. LAST2 play vital role in up regulating estrogen receptor,
and this cause resistance to tamoxifen. Studies shows that high level of TAZ were observed in breast cancer cells.\textsuperscript{60}

**Vault proteins associated genes**
Vaults are the largest nucleoprotein particle ever discovered which have a size of \(~42 \times 75\) nm and \(~13\) MDa mass. It is first described in 1986.\textsuperscript{61} Studies suggest that MVP protein have a particular role in drug resistance through the activation of MAP kinase pathway. MYP is the primary component of vault complex. It is involved in chemotherapy resistance by phosphoinositide-3-kinase/AKT signalling and EGFR induced MAPK pathway associated with \(ABCC1\) and \(ABCB1\). NOTCH1 down regulate MVP expression.

**Discussion**
Different genes play a crucial role in resistance to multiple drugs (Table 1). Genes related with MAP kinase pathways which include, GRMI, KLF4 etc have clear link with drug resistance in breast cancer. KLF4 knockdown cause tamoxifen resistance and STAT3 cause paclitaxel resistance. Another important members involved are ATP-binding cassette (ABC) transporters gene family which include \(ABCB1\), \(ABCG2\) and Multiple drug resistant gene family like \(MDR1\) genes. Chemotherapy resistance induced by preventing apoptosis is mediated by genes like \(FOXM1\), \(XIAP\), \(BIRC5\), \(XRCC2\), \(BRCA2\), \(CLDN6\), \(ASK1\), \(SIRT\), \(AMPK\), \(TWIST\) etc. Genes associated with hippo pathway and vault proteins associated genes induce drug resistance by various mechanisms. Conventional cancer chemotherapy is severely restricted by multidrug resistant tumor cells due to changes in the level or activity of membrane transporters that mediate energy dependent drug efflux and proteins that influence drug metabolism. The extensive use of chemotherapeutic agents for cancer treatment has led to many patients being cured. Sadly, many cancers do not yet respond to chemotherapy, and other cancers which initially respond later become resistant. The use of biologics and gene therapy is a highly active area of research to address the problems of chemo
resistance. Combination therapy, a type of treatment that incorporates two or more therapeutic agents, is one of the cornerstones of cancer treatment. Similar to the monotherapy strategy, the amalgamation of anti-cancer drugs increases effectiveness because it addresses main pathways in a synergistic or additive way. (Figure 4).

**Conclusion**

The drugs combinations which are currently exist were refined from clinical experiences and it comprises a small part of therapeutic space. Computational approach of the biological science to discover new collaborative drug combinations for treating breast cancer will help in overcome multiple drug resistance, rather than preventing drug resistance, it also prevents cell's mitotic activity, suppress the proliferation of cancer stem cells, reduce the rate of tumor formation and induce apoptosis. The five-year survival rates for most metastatic cancers are still quite small, so developing a new anti-cancer medication is costly and extremely time-consuming. Optimization of therapeutic efficacy by taking into account the therapeutic synergy that is immune to multiple drug dosing and scheduling can be carried out to overcome the acquired drug resistance in breast cancer patients.

**Ethical Issues**

No ethical issues are associated with the publication of this review article.

**Conflict of Interest**

Not applicable.

---

Table 1. Most studied genes involved in drug resistance in breast cancer

| Gene   | Important drugs                                      | Mechanism                                      | References |
|--------|-------------------------------------------------------|------------------------------------------------|------------|
| GRM1   | Doxycycline                                          | MAP kinase pathway alternation                 | 11         |
| KLF4   | Tamoxifen                                            | MAP kinase pathway alternation                 | 13         |
| STAT3  | Paclitaxel                                           | Alternation in apoptosis pathway               | 16         |
| ABCG2  | Doxorubicin, epirubicin, Anthracycline, gefitinib, erlotinib methotrexate | Drug efflux                                    | 22, 21     |
| ABCB1  | Cisplatin                                            | Drug efflux                                    | 62         |
| GPR120 | Epirubicin, anthracycline                            | Drug efflux                                    | 2          |
| MDR1   | Paclitaxel                                           | Alternating androgen receptor signaling        | 26         |
| FOXA1  | Tamoxifen                                            |                                                | 53         |
| TOP2A  | TOPOII Inhibitors                                    | Cell cycle alternation                         | 32         |
| CASP3  | Epirubicin, paclitaxel                               | Alternating apoptosis signaling                | 7          |
| RIF4   | Docetaxel                                            | Enhance cell proliferation                     | 66         |
| FOXM1  | Tamoxifen, anthracycline                             | Induce uncontrolled cell division              | 28         |
| XRCC2  | Cisplatin                                            | Apoptosis pathway                              | 27         |
| STRT3  | Taxol                                                | Preventing apoptosis                           | 45         |
| AMPK   | Taxol                                                | Apoptosis pathway alternation                  | 47         |
| GSTπ   | Cisplatin, paclitaxel                                | Drug inactivation                              | 52         |

---

![Figure 4. The amalgamation of anti-cancer drugs](image-url)
References

1. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT, et al. Identification of a novel function of TWIST, a βHIL protein, in the development of acquired taxol resistance in human cancer cells. *Oncogene* 2004;23(2):474-82. doi: 10.1088/sj.onc.1207128

2. Wang X, He S, Gu Y, Wang Q, Chu X, Jin M, et al. Fatty acid receptor GPR120 promotes breast cancer chemoresistance by upregulating ABC transporters expression and fatty acid synthesis. *EBioMedicine* 2019;40:251-62. doi: 10.1016/j.ebiom.2018.12.037

3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68(6):394-424. doi: 10.3322/caac.21492

4. Lu X, Gao C, Liu C, Zhuang J, Su P, Li H, et al. Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis. *Pathol Res Pract* 2019;215(8):152475. doi: 10.1016/j.prp.2019.152475

5. Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. *Lancet Oncol* 2009;10(11):1070-6. doi: 10.1016/s1470-2045(09)70254-2

6. Tanba J, Salarabadi H, Aznab M, Farahi A, Zoberi M. Relationship among prognostic indices of breast cancer using classification techniques. *Inform Med Unlocked* 2020;18:100265. doi: 10.1016/j.imu.2019.100265

7. Xiao YS, Zeng D, Liang YK, Wu Y, Li MF, Qi YZ, et al. Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells. *Cancer Lett* 2019;440-441:156-67. doi: 10.1016/j.canlet.2018.09.031

8. Bach DH, Hong JY, Park HJ, Lee SK. The role of exosomes and miRNAs in drug-resistance of cancer cells. *Int J Cancer* 2017;141(2):220-30. doi: 10.1002/ijc.30669

9. Li X, Wu X, Yang H, Li L, Ye Z, Yao R. A nuclear targeted Dox-aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer. *Biomed Pharmacother* 2019;117:109072. doi: 10.1016/j.biopha.2019.109072

10. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. *Cell Res* 2005;15(1):11-8. doi: 10.1038/sj.cr.7290257

11. Stires H, Heckler MM, Fu X, Li Z, Grasso CS, Quist MJ, et al. Integrated molecular analysis of tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGlur signaling as therapeutic vulnerabilities. *Mol Cell Endocrinol* 2018;471:105-17. doi: 10.1016/j.mce.2017.09.024

12. Martino JJ, Wall BA, Mastrantoni E, Willimczyk BJ, La Cava SN, Degenhardt K, et al. Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. *Oncogene* 2013;32(37):4366-76. doi: 10.1038/onc.2012.471

13. Jia Y, Zhou J, Luo X, Chen M, Chen Y, Wang J, et al. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer. *Cell Signal* 2018;42:165-75. doi: 10.1016/j.cellsig.2017.09.025

14. Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, Kolch W. Computational modelling of the receptor-tyro sine-kinase-activated MAPK pathway. *Biochem J* 2005;392(Pt 2):249-61. doi: 10.1042/bj0050908

15. Wang S, Yao Y, Yao M, Fu P, Wang W. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/ATK signaling pathways. *Biochem Biophys Res Commun* 2018;503(1):1605-9. doi: 10.1016/j.bbrc.2018.07.088

16. Campia I, Buondonno I, Castella B, Rolando B, Kopecka J, Gazzano E, et al. An autocrine cytokine/JAK/STAT-signaling induces kynurenine synthesis in multidrug resistant human breast cancer cells. *PloS One* 2015;10(5):e0126159. doi: 10.1371/journal.pone.0126159

17. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. *Methods Mol Biol* 2010;596:47-76. doi: 10.1007/978-1-60761-416-4

18. Choudhuri S, Kladden CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCG2 (MRP), and ABCG2 (BCRP) efflux transporters. *Int J Toxicol* 2006;25(4):231-59. doi: 10.1080/10915810600746023

19. Forrest AP, Stewart HJ, Everington D, Prescott R, McCardle CS, Harnett AN, et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. *Scottish Cancer Trials Breast Group. Lancet* 1996;348(9029):708-13. doi: 10.1016/s0140-6736(96)02133-2

20. Siti ZS, Sepapjor AM, Shahrol H. Lipoproteins modulate growth and P-glycoprotein expression in drug-resistant HER2-overexpressed breast cancer cells. *Helyon* 2019;5(4):e01573. doi: 10.1016/j.helyon.2019.e01573

21. Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, et al. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. *J Biol Chem* 2011;286(23):20558-68. doi: 10.1074/jbc.M111.240796

22. Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. *Adv Exp Med Biol* 2007;608:23-30. doi: 10.1007/978-0-387-74039-3_2

23. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. *Cancer Res* 2002;62(17):5035-40.

24. Velaei K, Samadi N, Soltani S, Barazvan B, Soleimani Rad J. NFκB/P65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer. *Breast Cancer Res Treat* 2017;144(5):523-61. doi: 10.1007/s12052-016-0738-8

25. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. *Endocr Relat Cancer* 2003;10(1):43-73. doi: 10.1677/erc.0.0100043

26. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, et al. Levels of multidrug resistance (mDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. *Clin Cancer Res* 1996;42(3):309-98.

27. Yang X, Uziely B, Groschen S, Lukas J, Israel V, Russell C, et al. MDRI gene expression in primary and advanced breast cancer. *Lab Invest* 1999;79(3):271-80.

28. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. *Endocr Relat Cancer* 2003;10(1):43-73. doi: 10.1677/erc.0.0100043

29. Giovannelli P, Di Donato M, Galasso G, Di Zazzo E, Bilancio A, Migliaccio A. The androgen receptor in breast cancer. *Endocr Relat Cancer* 2003;10(1):43-73. doi: 10.1677/erc.0.0100043
30. Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, et al. The lineage determining factor GRHL2 collaborates with FOXA1 to establish a targetable pathway in endocrine therapy-resistant breast cancer. Cell Rep 2019;29(4):889-903.e10. doi: 10.1016/j.celrep.2019.09.032

31. O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009;101(9):644-50. doi: 10.1093/jnci/djp067

32. Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg A, Grénman S, et al. Amplification and deletion of topoisomerase IIA isoform with Erb-B-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156(3):839-47. doi: 10.1016/s0002-9440(10)64952-8

33. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4(6):592-603. doi: 10.1038/nrc1412

34. Falschlechner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007;39(7-8):1462-75. doi: 10.1016/j.biocel.2007.02.007

35. Tiso N, Pallavicini A, Muraro T, Zimbello R, Apolloni E, Valle G, et al. Chromosomal localization of the human genes, CPP32, Mch2, Mch3, and Ich-1, involved in cellular apoptosis. Biochem Biophys Res Commun 1996;225(3):983-9. doi: 10.1006/bbrc.1996.1282

36. Pfefferle AD, Spike BT, Wahl GM, Perou CM. Luminal progenitor and fetal mammary stem cell expression features predict breast cancer tumor response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2015;149(2):425-37. doi: 10.1007/s10549-014-3262-6

37. Singel SM, Cornelius C, Zagajnar E, Batten K, Sarode VR, Buckley DL, et al. KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia 2014;16(3):247-56.e2. doi: 10.1016/j.neo.2014.03.008

38. de Moraes GN, Delheue D, Silva KL, Robaina MC, Khongkow P, Gomes AR, et al. FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance. Cell Signal 2015;27(12):2496-505. doi: 10.1016/j.cellsig.2015.09.013

39. Virrey JJ, Dong D, Stiles C, Patterson JB, Pen L, Ni M, et al. Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res 2008;6(8):1268-75. doi: 10.1158/1541-7786.mcr-08-0060

40. Fan CH, Liu WL, Cao H, Wen C, Chen L, Jiang G. O6-methylguanine DNA methyltransferase as a promising target in chemoresistance in human breast cancer. Biochim Biophys Acta 2007;1775(1):276-84. doi: 10.1016/j.bbadis.2006.11.083

41. Alavi AS, Acevedo L, Min W, Cheres DA. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res 2007;67(6):2766-72. doi: 10.1158/0008-5472.can-06-3648

42. Yang M, Li Y, Shen X, Ruan Y, Lu Y, Jin X, et al. CLDN6 promotes chemoresistance through GSP1 in human breast cancer. J Exp Clin Cancer Res 2017;36(1):157. doi: 10.1186/s13046-017-0627-9

43. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol 2007;27(24):8807-14. doi: 10.1128/mc.01636-07

44. Wang Z, Liu P, Chen Q, Deng S, Liu X, Situ H, et al. Targeting AMPK signaling pathway to overcome drug resistance for cancer therapy. Curr Drug Targets 2016;17(8):853-64. doi: 10.2174/13894501166661650316223655

45. Tomková V, Sandová-Acuña C, Torrelba N, Truska J. Mitochondrial fragmentation, elevated mitochondrial superoxide and respiratory supercomplexes disassembly is connected with the tamoxifen-resistant phenotype of breast cancer cells. Free Radic Biol Med 2019;143:510-21. doi: 10.1016/j.freeradbiomed.2019.09.004

46. Liu X, Han X, Wan X, He C, Wang Y, Mao A, et al. SPZ1 is critical for chemoresistance and aggressiveness in drug-resistant breast cancer cells. Biochem Pharmacol 2018;156:43-51. doi: 10.1016/j.bcp.2018.07.046

47. Fedier A, Schwarz VA, Wall H, Carpini RD, Haller U, Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001;94(4):571-6. doi: 10.1002/jic.1356

48. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diaminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993;268(27):20116-25. doi: 10.1002/jbc.26820116-25

49. Choy BK, McClarty GA, Chan AK, Thelander L, Wright JA. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations. Cancer Res 1988;48(8):2029-35.

50. Chen SY, Hu SS, Dong Q, Cai JX, Zhang WP, Sun JY, et al. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo. Asian Pac J Cancer Prev 2013;14(10):6135-40. doi: 10.7314/apjcp.2013.14.6135

51. Hamada S, Kamada M, Furumoto H, Hirao T, Aono T. Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 1994;52(3):313-9. doi: 10.1006/gyno.1994.1055

52. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5(4):275-84. doi: 10.1038/nrc1590

53. Blanpain C, Lowry WE, Geoghegan A, Polak L, Fuchs E. Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell 2004;118(5):635-48. doi: 10.1016/j.cell.2004.08.012

54. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by human immature hematopoietic progenitors. Blood 2002;99(2):507-12. doi: 10.1182/blood.v99.2.507

55. Lee KM, Giltinan JM, Balko JM, Schwarz LJ, Guererro-Zotano AL, Hutchinson KE, et al. MYC and MCL1 cooperatively promote chemoresistant-breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation.
Chemotherapeutic resistance genes

58. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. *Science* 2011;331(6024):1559-64. doi: 10.1126/science.1203543

59. Pan D. The hippo signaling pathway in development and cancer. *Dev Cell* 2010;19(4):491-505. doi: 10.1016/j.devcel.2010.09.011

60. Maugeri-Saccà M, De Maria R. Hippo pathway and breast cancer stem cells. *Crit Rev Oncol Hematol* 2016;99:115-22. doi: 10.1016/j.critrevonc.2015.12.004

61. Kedersha NL, Heuser JE, Chugani DC, Rome LH. Vaults. III. Vault ribonucleoprotein particles open into flower-like structures with octagonal symmetry. *J Cell Biol* 1991;112(2):225-35. doi: 10.1083/jcb.112.2.225

62. Sun KX, Jiao JW, Chen S, Liu BL, Zhao Y. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. *J Ovarian Res* 2015;8:80. doi: 10.1186/s13048-015-0207-6

63. Tan MH, De S, Bebek G, Orloff MS, Wesolowski R, Downs-Kelly E, et al. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. *Breast Cancer Res Treat* 2012;131(3):849-58. doi: 10.1007/s10549-011-1500-8